Curanex Pharmaceuticals

CURX

Market cap $12.4M

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) resulting from allegations that Curanex may have issued materially misleading business information to the investing public. So what: If you purchased Curanex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) resulting from allegations that Curanex may have issued materially misleading business information to the investing public. So what: If you purchased Curanex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr.

Expanded case series includes advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease

Case involving senior dosimetrist at a premier cancer hospital in the Northeast suggests potential relevance of Phyto-N in one of oncology's most serious and underserved supportive-care markets

Company expands strategic focus into one of oncology's  most urgent supportive-care challenges Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage therapeutics company, today announced that it is expanding its drug development pipeline that encompassed six core indications: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease (“NAFLD”), and gout, by focusing on a new core indication: cancer cachexia, a serious cancer-associated wasting syndrome marked by progressive weight loss, muscle depletion, weakness and declining physical function. Cancer cachexia is widely recognized as one of the most serious complications in oncology and is estimated by the National Cancer Institute to occur in up to 80% of patients with advanced cancer, depending on cancer type and response to treatment.

Company advances manufacturing, toxicology, patent and regulatory milestones while building a broader pharmaceutical development platform

Phyto-N 28-Day Repeat-Dose Study in Rats and Dogs Shows No Findings of Toxicological Significance at Maximum Feasible Dose, Enabling Advancement to GLP Toxicology Program Jericho, New York, March 18, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for inflammatory diseases, today announced the successful completion of a dose-range finding toxicology study of its lead botanical drug candidate, Phyto-N, conducted in Sprague-Dawley rats and dogs. The study evaluated repeat-dose oral tolerability over 28 days and is designed to inform dose selection and study design for the Company's subsequent Good Laboratory Practice (GLP)-compliant toxicology studies required for its planned Investigational New Drug (IND) application, which the Company targets to submit in the fourth quarter of 2026.

New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy

New Advisors Bring 50+ Years of Leadership Experience  With 2 of the Top 10 Global Pharmaceuticals Companies Jericho, New York, March 11, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the appointment of two highly respected and accomplished life sciences research experts to the Company's Scientific Advisory Board. Together, Dr. Daniel Pascheles and Dr. Nicholas A.

Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho, New York, March 05, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the formation of a new Scientific Advisory Board, reporting to and supporting the executive team and Board of Directors of Curanex. The purpose of this Scientific Advisory Board will be two-fold.